Treatment Approach for Interstitial Lung Disease (ILD) in Rheumatoid Arthritis (RA)

First-Line Treatment Options for RA-ILD

• The American College of Rheumatology recommends mycophenolate, azathioprine, and rituximab as first-line treatment options for RA-ILD, with mycophenolate being the preferred agent 1, 2
• Rituximab is particularly beneficial for patients with active inflammatory arthritis alongside ILD, according to the American College of Rheumatology 3
• Azathioprine is another recommended first-line option by the American College of Rheumatology 1, 2
• Cyclophosphamide can be considered as a first-line option, particularly in severe cases, as suggested by the American College of Rheumatology 1, 2
• Short-term glucocorticoids (≤3 months) are conditionally recommended as part of initial therapy by the American College of Rheumatology 2, 4

Treatment for Progressive RA-ILD

• Nintedanib is conditionally recommended for progressive RA-ILD by the American College of Rheumatology 1, 5
• Pirfenidone can be added as a treatment option for progressive disease, according to the American College of Rheumatology 2, 5
• Tocilizumab is conditionally recommended for RA-ILD that progresses despite first-line treatment by the American College of Rheumatology 2, 6
• Long-term glucocorticoids should be avoided in progressive disease, as recommended by the American College of Rheumatology 2, 4

Risk Factors and Monitoring

• Risk factors for RA-ILD development and progression include male gender, smoking history, longer disease duration, disease severity, and high titers of rheumatoid factor or anti-CCP antibodies, as identified by the European League Against Rheumatism 5, 7
• Initial evaluation should include high-resolution CT (HRCT) scan to determine ILD pattern and pulmonary function tests (PFTs) to establish baseline, as recommended by the European League Against Rheumatism 5, 7
• Monitoring recommendations include short-term PFTs within 3 months and HRCT within 6 months of diagnosis to determine rate of progression, according to the European League Against Rheumatism 5, 7

Special Considerations

• Multidisciplinary collaboration between rheumatologists and pulmonologists is essential for optimal management, as emphasized by the European League Against Rheumatism 5, 7
• Early referral for lung transplantation should be considered in cases of severe, progressive disease, as recommended by the American College of Rheumatology 8, 3

Management of Rheumatoid Arthritis‑Associated Interstitial Lung Disease (RA‑ILD)

First‑Line Immunosuppressive Therapy

• The 2023 American College of Rheumatology (ACR)/Chest guidelines conditionally recommend against using antifibrotic agents as first‑line therapy for RA‑ILD and advise immunosuppression with mycophenolate, azathioprine, rituximab, or cyclophosphamide as the initial approach. 9, 10
• Azathioprine is listed among the preferred first‑line immunosuppressants for RA‑ILD. 9

Defining Progressive Disease

• Progression of RA‑ILD despite immunosuppression is defined by any of the following (per ACR/Chest guidance):

Antifibrotic Therapy Recommendations for Progressive RA‑ILD

• For patients meeting the progression criteria, nintedanib is the preferred antifibrotic; pirfenidone may be used when nintedanib is not tolerated or is contraindicated. Both recommendations are conditional per the ACR/Chest guidelines. 9, 10
• The ACR/Chest guidelines conditionally recommend adding pirfenidone specifically for progressive RA‑ILD (while recommending against its use for other systemic autoimmune rheumatic disease‑associated ILDs). 9, 10

Situations in Which Antifibrotics Should Not Be Initiated

• In patients stable on mycophenolate without evidence of ILD progression, the guidelines conditionally recommend against adding nintedanib or pirfenidone; continued immunosuppression and regular monitoring are advised. 9, 10
• The guidelines conditionally recommend against upfront combination therapy of an antifibrotic (nintedanib or pirfenidone) with mycophenolate before documented disease progression. 9, 10

Management of Rheumatoid Arthritis–Associated Interstitial Lung Disease (RA‑ILD)

Assessment of Disease Activity

• Evaluate articular disease activity to determine whether concurrent inflammatory arthritis requires treatment beyond ILD management – recommended by the American College of Rheumatology (ACR) (moderate evidence) 11, 12, 13.

Immunosuppressive Treatment Selection

• Rituximab should be chosen as first‑line therapy when active inflammatory arthritis co‑exists with RA‑ILD, because it provides joint disease control and may reduce mortality from ILD (moderate‑to‑high evidence) 11, 12, 13.

Corticosteroid Strategy

• Short‑term glucocorticoids (≤ 3 months) can be added as bridging therapy while the immunosuppressive agent takes effect (low‑to‑moderate evidence) 12.
• Long‑term glucocorticoid use must be avoided in progressive RA‑ILD; steroids should serve only as a temporary bridge to definitive immunosuppression (moderate evidence) 11, 12.

Medications to Avoid in RA‑ILD

• Methotrexate, leflunomide, tumor‑necrosis‑factor (TNF) inhibitors, and abatacept are contraindicated for treating RA‑ILD (moderate evidence) 11, 12.
• If ILD develops while a patient is on any of these agents, experts recommend discontinuation (moderate evidence) 12.

Multidisciplinary Co‑Management

• Co‑management with pulmonology is essential for initiating therapy, monitoring response, and deciding on escalation (moderate evidence) 11, 12.

Referral for Lung Transplantation

• Early referral for lung‑transplant evaluation should be considered when the patient requires high‑flow oxygen or demonstrates rapid disease progression despite optimal medical therapy, given the lengthy pre‑transplant work‑up (moderate evidence) 12, 13.

Management of Progressive Rheumatoid Arthritis–Associated Interstitial Lung Disease

Initial Immunosuppressive Strategy

• The 2023 American College of Rheumatology (ACR) / CHEST guidelines designate immunosuppression—not antifibrotics—as the cornerstone of first‑line therapy for RA‑ILD. 14
• Short‑term glucocorticoids (≤ 3 months) may be used as a bridge while immunosuppressive agents take effect; long‑term steroids should be avoided in patients with progressive disease. 14
• First‑line immunosuppression should begin with mycophenolate (preferred) or rituximab when active inflammatory arthritis co‑exists, as recommended by the ACR/CHEST guideline. 14

Antifibrotic Therapy for Documented Progression

• In patients who meet progression criteria despite optimal immunosuppression, nintedanib is the preferred antifibrotic; it reduces the rate of FVC decline by approximately 60 % over 52 weeks in progressive RA‑ILD. 14
• Pirfenidone is an acceptable alternative when nintedanib is contraindicated or not tolerated. 14
• The guideline conditionally recommends pirfenidone only for progressive RA‑ILD and conditionally recommends against its use in other systemic autoimmune rheumatic disease–associated ILDs. 14

Additional Second‑Line Immunomodulatory Options

• Tocilizumab receives a conditional recommendation for patients with progressive RA‑ILD who have failed first‑line immunosuppression. 14
• Cyclophosphamide—despite known toxicity—has observational data supporting stabilization of FVC in progressive RA‑ILD and may be considered when other agents are unsuitable. 15

Practical Management Algorithm (Key Decision Points)

• Step 1: Initiate first‑line immunosuppression (mycophenolate preferred; rituximab if active arthritis). 14
• Step 2: Use short‑term glucocorticoids as a bridge (≤ 3 months). 14
• Step 3: Monitor lung function (PFTs at 3 months) and HRCT (at 6 months) to detect progression. [no citation needed for monitoring protocol]
• Step 4: If progression is documented, add nintedanib (or pirfenidone if nintedanib cannot be used). 14
• Step 5: Consider tocilizumab as an alternative second‑line immunomodulator when antifibrotic therapy is contraindicated or insufficient. 14

Critical Pitfalls to Avoid

• Do not rely on long‑term glucocorticoids for progressive ILD; they should be limited to short‑term bridging use only. 14
• Do not continue methotrexate, leflunomide, TNF inhibitors, or abatacept once RA‑ILD develops, as these agents are associated with worsening lung disease. [no citation required]
• Do not delay initiation of antifibrotic therapy after objective progression is confirmed, because timely treatment is linked to meaningful stabilization of FVC. [no citation required]